JWA
DNLI icon

JFS Wealth Advisors’s Denali Therapeutics DNLI Stock Holding History

JFS Wealth Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.31K Buy
51
+43
+538% +$884 ﹤0.01% 1740
2026
Q1 		$154 Hold
8
– – ﹤0.01% 1831
2025
Q4 		$133 Buy
+8
New +$135 ﹤0.01% 1879
2022
Q1 		– Sell
-14
Closed -$1K – 1855
2021
Q4 		$1K Buy
+14
New +$663 ﹤0.01% 1326

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JFS Wealth Advisors's DNLI Position: Q2 2026 in Review

JFS Wealth Advisors increased its Denali Therapeutics (DNLI) stake by 538% in Q2 2026, buying an estimated $884 and bringing the position to 51 shares worth $1.31K. The position accounts for ﹤0.01% of the portfolio, ranked #1740.

JFS Wealth Advisors first reported a position in DNLI in Q4 2021 and has held it in 4 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • JFS Wealth Advisors held 51 shares of Denali Therapeutics worth $1.31K as of Q2 2026.
  • JFS Wealth Advisors bought 43 Denali Therapeutics shares in Q2 2026, an estimated $884.
  • Denali Therapeutics made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q2 2026, its #1740 holding.
  • JFS Wealth Advisors first reported a position in Denali Therapeutics in Q4 2021 and has held it in 4 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on JFS Wealth Advisors's 13F filing for Q2 2026, filed 10 Jul 2026.